17-10-2018
sudok1 / iStockphoto.com
The US Food and Drug Administration (FDA) has allowed the first US-based human trial of CRISPR, the gene-editing technology, to proceed.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Food and Drug Administration, CRISPR, gene-editing technology, CRISPR Therapeutics, Vertex Pharmaceutics, sickle cell disease, β-thalassemia, study
Google fund invests in CRISPR start-up
14-05-2019
US university treats cancer patients with CRISPR
17-04-2019
AstraZeneca to launch CRISPR-based cancer research centre
11-12-2018
Scientists want CRISPR regulation amid reports of foetus gene-editing
26-11-2018
CRISPR tech market to reach $1.72m by 2023: report
23-11-2018
Vertex and CRISPR Therapeutics to develop gene-editing treatment
14-12-2017
Vertex and CRISPR Therapeutics announce research partnership
26-10-2015
